Although no further analysis was carried out to address the functional role of this genetic alteration during tumor progression, it is very tempting to speculate that this particular rearrangement involving TP53BP-2 constitutes a driver genetic event associated with disease progression and dissemination after nCRT. This evidence concerns the gene TP53BP2 and neoplasm.